Variables used for the determination of the ISAPL
| Variables analyzed . | Dichotomization strategy . | Cox proportional hazard modeling . | Integer weight* . |
|---|---|---|---|
| HR (95% CI); P . | |||
| FLT3-ITD status: mutated vs nonmutated | Not applicable | 2.88 (1.55-5.35); .001 | 3 |
| KMT2E gene expression: low vs high | Q1-Q2 vs Q3-Q4 | 3.26 (1.18-8.99); .022 | 3 |
| BAALC gene expression: high vs low | Q3-Q4 vs Q1-Q2 | 2.68 (1.04-6.92); .041 | 3 |
| ΔNp73/TAp73 ratio: high vs low | Q4 vs Q1-Q3 | 4.43 (1.83-10.7); .001 | 3 |
| ID1 gene expression: high vs low | Q4 vs Q1-Q3 | 3.41 (1.42-8.22); .006 | 3 |
| ERG gene expression: low vs high | Q1 vs Q2-Q4 | 2.65 (1.15-6.42); .03 | 3 |
| WT1 gene expression: low vs high | Q1 vs Q2-Q4 | 6.78 (0.9-50.7); .061 | — |
| PRAME gene expression: high vs low | Q3-Q4 vs Q1-Q2 | 1.02 (0.42-2.45); .96 | — |
| PIM2 gene expression: high vs low | Q3-Q4 vs Q1-Q2 | 1.23 (0.5-2.96); .644 | — |
| Variables analyzed . | Dichotomization strategy . | Cox proportional hazard modeling . | Integer weight* . |
|---|---|---|---|
| HR (95% CI); P . | |||
| FLT3-ITD status: mutated vs nonmutated | Not applicable | 2.88 (1.55-5.35); .001 | 3 |
| KMT2E gene expression: low vs high | Q1-Q2 vs Q3-Q4 | 3.26 (1.18-8.99); .022 | 3 |
| BAALC gene expression: high vs low | Q3-Q4 vs Q1-Q2 | 2.68 (1.04-6.92); .041 | 3 |
| ΔNp73/TAp73 ratio: high vs low | Q4 vs Q1-Q3 | 4.43 (1.83-10.7); .001 | 3 |
| ID1 gene expression: high vs low | Q4 vs Q1-Q3 | 3.41 (1.42-8.22); .006 | 3 |
| ERG gene expression: low vs high | Q1 vs Q2-Q4 | 2.65 (1.15-6.42); .03 | 3 |
| WT1 gene expression: low vs high | Q1 vs Q2-Q4 | 6.78 (0.9-50.7); .061 | — |
| PRAME gene expression: high vs low | Q3-Q4 vs Q1-Q2 | 1.02 (0.42-2.45); .96 | — |
| PIM2 gene expression: high vs low | Q3-Q4 vs Q1-Q2 | 1.23 (0.5-2.96); .644 | — |
Integer weights for the risk score were derived from the Cox proportional hazard model, using overall survival as the end point.